Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
Announcement follows completion of global manufacturing review and decision to invest in expanded manufacturing capacity
Read more -
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
GSK announced new data from the DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme
Read more -
FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
An approval would give Nucala a third indication in an eosinophil-driven disease
Read more -
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing.
Read more -
GSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020
26 abstracts across 8 tumour types, advancing GSK’s goal of maximising outcomes for patients
Read more -
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Ovarian cancer press release
Read more -
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
Read more -
GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congress
Read more -
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.
Read more -
Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis
Voltaren Arthritis Pain will donate 100% of pre-order profits up to $100k to the Arthritis Foundation
Read more -
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks
Read more -
Update on GSK actions to support the global response to COVID-19
As a leader in science and innovation, we are helping to contribute to the fight against COVID-19 with one of our advanced vaccine adjuvant systems.
Read more -
GSK appoints Charles Bancroft to the Board as a Non-Executive Director
GlaxoSmithKline plc today announced that Charles Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
Read more -
ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV
ViiV Healthcare, today announced that Health Canada has approved CABENUVA.
Read more -
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1
ViiV Healthcare presents positive long-term data from phase III study
Read more -
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
ViiV Healthcare presents positive 48-week data from phase III study
Read more -
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership
Read more -
FDA approves GSK’s Advil Dual Action with Acetaminophen for over-the-counter use in the United States
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) p...
Read more -
ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a study in par...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
